When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
KALA - Kala Pharma completes enrollment in late-stage study of Eysuvis in dry eye disease
Kala Pharmaceuticals Inc.
Kala Pharmaceuticals (NASDAQ:KALA) has completed enrollment of ~900 patients in its STRIDE 3 (Short Term Relief In Dry Eye) Phase 3 clinical trial for KPI-121 0.25%, for the short-term treatment of dry eye disease.
More news on: Kala Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move,